Subcutaneous furosemide pump strategy increased days alive out of hospital

A UK multicenter randomized trial (SUBCUT-HF II) compared an early discharge strategy using a wearable subcutaneous furosemide minipump against usual care in 172 patients hospitalized for heart failure requiring ongoing parenteral diuretics. The trial reported 4.0 more days alive and out of hospital at 30 days with early discharge, a 5.5-day shorter index hospitalization, and a sustained benefit at 60 days, though heart failure readmissions were more frequent in the early discharge group (14% vs 6%); serious adverse events were similar between groups and device-related problems occurred in 3% of minipump placements, none serious.

Most relevant for: Patients hospitalized for heart failure who require ongoing intravenous diuretic therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.